Evaluating  ||| S:0 E:11 ||| VBG
the  ||| S:11 E:15 ||| DT
effects  ||| S:15 E:23 ||| NNS
of  ||| S:23 E:26 ||| IN
amantadin ||| S:26 E:35 ||| NN
,  ||| S:35 E:37 ||| ,
modafinil  ||| S:37 E:47 ||| NN
and  ||| S:47 E:51 ||| CC
acetyl-L-carnitine  ||| S:51 E:70 ||| JJ
on  ||| S:70 E:73 ||| IN
fatigue  ||| S:73 E:81 ||| NN
in  ||| S:81 E:84 ||| IN
multiple  ||| S:84 E:93 ||| JJ
sclerosis--result  ||| S:93 E:111 ||| NN
of  ||| S:111 E:114 ||| IN
a  ||| S:114 E:116 ||| DT
pilot  ||| S:116 E:122 ||| NN
randomized ||| S:122 E:132 ||| NN
,  ||| S:132 E:134 ||| ,
blind  ||| S:134 E:140 ||| JJ
study  ||| S:140 E:146 ||| NN
Fatigue  ||| S:146 E:154 ||| NNP
affects  ||| S:154 E:162 ||| VBZ
more  ||| S:162 E:167 ||| JJR
than  ||| S:167 E:172 ||| IN
60 ||| S:172 E:174 ||| CD
%  ||| S:174 E:176 ||| NN
of  ||| S:176 E:179 ||| IN
multiple  ||| S:179 E:188 ||| JJ
sclerosis  ||| S:188 E:198 ||| NNS
( ||| S:198 E:199 ||| -LRB-
MS ||| S:199 E:201 ||| NNP
)  ||| S:201 E:203 ||| -RRB-
patients  ||| S:203 E:212 ||| NNS
and  ||| S:212 E:216 ||| CC
is  ||| S:216 E:219 ||| VBZ
one  ||| S:219 E:223 ||| CD
of  ||| S:223 E:226 ||| IN
the  ||| S:226 E:230 ||| DT
most  ||| S:230 E:235 ||| RBS
troublesome  ||| S:235 E:247 ||| JJ
symptoms  ||| S:247 E:256 ||| NNS
of  ||| S:256 E:259 ||| IN
the  ||| S:259 E:263 ||| DT
disease ||| S:263 E:270 ||| NN
.  ||| S:270 E:272 ||| .
Current  ||| S:272 E:280 ||| JJ
treatment  ||| S:280 E:290 ||| NN
options  ||| S:290 E:298 ||| NNS
for  ||| S:298 E:302 ||| IN
MS  ||| S:302 E:305 ||| NNP
fatigue  ||| S:305 E:313 ||| NNS
include  ||| S:313 E:321 ||| VBP
amantadine ||| S:321 E:331 ||| VBN
,  ||| S:331 E:333 ||| ,
modafinil  ||| S:333 E:343 ||| NN
and  ||| S:343 E:347 ||| CC
acetyl-l-carnitine  ||| S:347 E:366 ||| NNP
( ||| S:366 E:367 ||| -LRB-
ALCAR ||| S:367 E:372 ||| NNP
) ||| S:372 E:373 ||| -RRB-
.  ||| S:373 E:375 ||| .
The  ||| S:375 E:379 ||| DT
aim  ||| S:379 E:383 ||| NN
of  ||| S:383 E:386 ||| IN
our  ||| S:386 E:390 ||| PRP$
study  ||| S:390 E:396 ||| NN
was  ||| S:396 E:400 ||| VBD
to  ||| S:400 E:403 ||| TO
compare  ||| S:403 E:411 ||| VB
efficacy  ||| S:411 E:420 ||| VBN
of  ||| S:420 E:423 ||| IN
amantadine ||| S:423 E:433 ||| NN
,  ||| S:433 E:435 ||| ,
modafinil  ||| S:435 E:445 ||| NN
and  ||| S:445 E:449 ||| CC
ALCAR  ||| S:449 E:455 ||| NNP
with  ||| S:455 E:460 ||| IN
placebo  ||| S:460 E:468 ||| NN
in  ||| S:468 E:471 ||| IN
patients  ||| S:471 E:480 ||| NNS
with  ||| S:480 E:485 ||| IN
MS ||| S:485 E:487 ||| NNP
.  ||| S:487 E:489 ||| .
Patients  ||| S:489 E:498 ||| NNS
with  ||| S:498 E:503 ||| IN
MS  ||| S:503 E:506 ||| NNP
and  ||| S:506 E:510 ||| CC
a  ||| S:510 E:512 ||| DT
disability  ||| S:512 E:523 ||| NN
level  ||| S:523 E:529 ||| NN
≤  ||| S:529 E:531 ||| CD
5.5  ||| S:531 E:535 ||| CD
on  ||| S:535 E:538 ||| IN
the  ||| S:538 E:542 ||| DT
Kurtzke  ||| S:542 E:550 ||| NNP
Expanded  ||| S:550 E:559 ||| NNP
Disability  ||| S:559 E:570 ||| NNP
Status  ||| S:570 E:577 ||| NNP
Scale  ||| S:577 E:583 ||| NNP
( ||| S:583 E:584 ||| -LRB-
EDSS ||| S:584 E:588 ||| NNP
)  ||| S:588 E:590 ||| -RRB-
and  ||| S:590 E:594 ||| CC
fatigue  ||| S:594 E:602 ||| NNS
were  ||| S:602 E:607 ||| VBD
included  ||| S:607 E:616 ||| VBN
in  ||| S:616 E:619 ||| IN
the  ||| S:619 E:623 ||| DT
study ||| S:623 E:628 ||| NN
.  ||| S:628 E:630 ||| .
Patients  ||| S:630 E:639 ||| NNS
were  ||| S:639 E:644 ||| VBD
assigned  ||| S:644 E:653 ||| VBN
to  ||| S:653 E:656 ||| TO
a  ||| S:656 E:658 ||| DT
one  ||| S:658 E:662 ||| CD
month  ||| S:662 E:668 ||| NN
treatment  ||| S:668 E:678 ||| NN
with  ||| S:678 E:683 ||| IN
either  ||| S:683 E:690 ||| DT
amantadine  ||| S:690 E:701 ||| JJ
200mg ||| S:701 E:706 ||| NN
,  ||| S:706 E:708 ||| ,
ALCAR  ||| S:708 E:714 ||| NNP
2g ||| S:714 E:716 ||| NNP
,  ||| S:716 E:718 ||| ,
modafinil  ||| S:718 E:728 ||| JJ
200mg  ||| S:728 E:734 ||| NN
or  ||| S:734 E:737 ||| CC
placebo ||| S:737 E:744 ||| NN
.  ||| S:744 E:746 ||| .
Efficacy  ||| S:746 E:755 ||| NNP
of  ||| S:755 E:758 ||| IN
the  ||| S:758 E:762 ||| DT
treatment  ||| S:762 E:772 ||| NN
was  ||| S:772 E:776 ||| VBD
evaluated  ||| S:776 E:786 ||| VBN
by  ||| S:786 E:789 ||| IN
using  ||| S:789 E:795 ||| VBG
the  ||| S:795 E:799 ||| DT
modified  ||| S:799 E:808 ||| JJ
fatigue  ||| S:808 E:816 ||| JJ
impact  ||| S:816 E:823 ||| NN
scale  ||| S:823 E:829 ||| NN
( ||| S:829 E:830 ||| -LRB-
MFIS ||| S:830 E:834 ||| NNP
) ||| S:834 E:835 ||| -RRB-
.  ||| S:835 E:837 ||| .
Sixty  ||| S:837 E:843 ||| JJ
patients  ||| S:843 E:852 ||| NNS
were  ||| S:852 E:857 ||| VBD
included  ||| S:857 E:866 ||| VBN
in  ||| S:866 E:869 ||| IN
the  ||| S:869 E:873 ||| DT
study  ||| S:873 E:879 ||| NN
( ||| S:879 E:880 ||| -LRB-
39  ||| S:880 E:883 ||| CD
females ||| S:883 E:890 ||| NNS
) ||| S:890 E:891 ||| -RRB-
.  ||| S:891 E:893 ||| .
The  ||| S:893 E:897 ||| DT
mean  ||| S:897 E:902 ||| JJ
age  ||| S:902 E:906 ||| NN
of  ||| S:906 E:909 ||| IN
patients  ||| S:909 E:918 ||| NNS
was  ||| S:918 E:922 ||| VBD
38  ||| S:922 E:925 ||| CD
±  ||| S:925 E:927 ||| CD
6.7  ||| S:927 E:931 ||| CD
years  ||| S:931 E:937 ||| NNS
and  ||| S:937 E:941 ||| CC
the  ||| S:941 E:945 ||| DT
mean  ||| S:945 E:950 ||| JJ
disease  ||| S:950 E:958 ||| NN
duration  ||| S:958 E:967 ||| NN
was  ||| S:967 E:971 ||| VBD
6.6  ||| S:971 E:975 ||| CD
±  ||| S:975 E:977 ||| CD
1.2  ||| S:977 E:981 ||| CD
years ||| S:981 E:986 ||| NNS
.  ||| S:986 E:988 ||| .
Contrast  ||| S:988 E:997 ||| NN
analysis  ||| S:997 E:1006 ||| NN
showed  ||| S:1006 E:1013 ||| VBD
significantly  ||| S:1013 E:1027 ||| RB
lower  ||| S:1027 E:1033 ||| RBR
mean  ||| S:1033 E:1038 ||| JJ
MFIS  ||| S:1038 E:1043 ||| NNP
score  ||| S:1043 E:1049 ||| NN
after  ||| S:1049 E:1055 ||| IN
one  ||| S:1055 E:1059 ||| CD
month  ||| S:1059 E:1065 ||| NN
in  ||| S:1065 E:1068 ||| IN
patients  ||| S:1068 E:1077 ||| NNS
on  ||| S:1077 E:1080 ||| IN
amantadine  ||| S:1080 E:1091 ||| VBG
compared  ||| S:1091 E:1100 ||| VBN
to  ||| S:1100 E:1103 ||| TO
placebo  ||| S:1103 E:1111 ||| VB
( ||| S:1111 E:1112 ||| -LRB-
mean  ||| S:1112 E:1117 ||| VB
difference=17.3 ||| S:1117 E:1132 ||| CD
,  ||| S:1132 E:1134 ||| ,
p=0.001 ||| S:1134 E:1141 ||| CD
) ||| S:1141 E:1142 ||| -RRB-
.  ||| S:1142 E:1144 ||| .
There  ||| S:1144 E:1150 ||| EX
was  ||| S:1150 E:1154 ||| VBD
also  ||| S:1154 E:1159 ||| RB
a  ||| S:1159 E:1161 ||| DT
trend  ||| S:1161 E:1167 ||| NN
of  ||| S:1167 E:1170 ||| IN
a  ||| S:1170 E:1172 ||| DT
lower  ||| S:1172 E:1178 ||| JJR
MFIS  ||| S:1178 E:1183 ||| JJ
score  ||| S:1183 E:1189 ||| NN
in  ||| S:1189 E:1192 ||| IN
ALCAR  ||| S:1192 E:1198 ||| NNP
group  ||| S:1198 E:1204 ||| NN
in  ||| S:1204 E:1207 ||| IN
comparison  ||| S:1207 E:1218 ||| NN
to  ||| S:1218 E:1221 ||| TO
placebo  ||| S:1221 E:1229 ||| VB
( ||| S:1229 E:1230 ||| -LRB-
mean  ||| S:1230 E:1235 ||| VB
difference=12.4 ||| S:1235 E:1250 ||| CD
,  ||| S:1250 E:1252 ||| ,
p=0.05 ||| S:1252 E:1258 ||| NNP
,  ||| S:1258 E:1260 ||| ,
with  ||| S:1260 E:1265 ||| IN
Keppel-corrected  ||| S:1265 E:1282 ||| JJ
alpha  ||| S:1282 E:1288 ||| NN
of  ||| S:1288 E:1291 ||| IN
0.046 ||| S:1291 E:1296 ||| CD
) ||| S:1296 E:1297 ||| -RRB-
.  ||| S:1297 E:1299 ||| .
The  ||| S:1299 E:1303 ||| DT
quality  ||| S:1303 E:1311 ||| NN
of  ||| S:1311 E:1314 ||| IN
life  ||| S:1314 E:1319 ||| NN
measured  ||| S:1319 E:1328 ||| VBN
as  ||| S:1328 E:1331 ||| IN
SF  ||| S:1331 E:1334 ||| NNP
36  ||| S:1334 E:1337 ||| CD
-  ||| S:1337 E:1339 ||| :
PCS  ||| S:1339 E:1343 ||| NNP
and  ||| S:1343 E:1347 ||| CC
SF  ||| S:1347 E:1350 ||| NNP
36  ||| S:1350 E:1353 ||| CD
-  ||| S:1353 E:1355 ||| :
MCS  ||| S:1355 E:1359 ||| NNP
proved  ||| S:1359 E:1366 ||| VBD
to  ||| S:1366 E:1369 ||| TO
be  ||| S:1369 E:1372 ||| VB
significantly  ||| S:1372 E:1386 ||| RB
influenced  ||| S:1386 E:1397 ||| VBN
by  ||| S:1397 E:1400 ||| IN
treatment ||| S:1400 E:1409 ||| NN
.  ||| S:1409 E:1411 ||| .
One  ||| S:1411 E:1415 ||| CD
month  ||| S:1415 E:1421 ||| NN
treatment  ||| S:1421 E:1431 ||| NN
with  ||| S:1431 E:1436 ||| IN
amantadine  ||| S:1436 E:1447 ||| JJ
improved  ||| S:1447 E:1456 ||| JJ
fatigue  ||| S:1456 E:1464 ||| NN
in  ||| S:1464 E:1467 ||| IN
patients  ||| S:1467 E:1476 ||| NNS
with  ||| S:1476 E:1481 ||| IN
relapsing-remitting  ||| S:1481 E:1501 ||| NNP
MS  ||| S:1501 E:1504 ||| NNP
as  ||| S:1504 E:1507 ||| RB
evaluated  ||| S:1507 E:1517 ||| VBN
by  ||| S:1517 E:1520 ||| IN
MFIS ||| S:1520 E:1524 ||| NNP
.  ||| S:1524 E:1526 ||| .
No  ||| S:1526 E:1529 ||| RB
or  ||| S:1529 E:1532 ||| CC
only  ||| S:1532 E:1537 ||| RB
a  ||| S:1537 E:1539 ||| DT
trend  ||| S:1539 E:1545 ||| NN
of  ||| S:1545 E:1548 ||| IN
improvement  ||| S:1548 E:1560 ||| NN
was  ||| S:1560 E:1564 ||| VBD
seen  ||| S:1564 E:1569 ||| VBN
in  ||| S:1569 E:1572 ||| IN
patients  ||| S:1572 E:1581 ||| NNS
treated  ||| S:1581 E:1589 ||| VBN
with  ||| S:1589 E:1594 ||| IN
modafinil  ||| S:1594 E:1604 ||| NN
or  ||| S:1604 E:1607 ||| CC
ALCAR ||| S:1607 E:1612 ||| NNP
,  ||| S:1612 E:1614 ||| ,
respectively ||| S:1614 E:1626 ||| RB
.  ||| S:1626 E:1628 ||| .
